- The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)2004 | Second Faculty of Medicine
- External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score2021 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial2010 | Third Faculty of Medicine
- Treatment of patients with myelodysplastic syndrome with iron overload oral chelator deferasirox2013 | First Faculty of Medicine
- Current therapeutic approaches in myelodysplastic sydrome2009 | Publication without faculty affiliation
- Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome2021 | Faculty of Medicine in Hradec Králové
- Treatment strategies for myelodysplastic syndrome in 20212021 | Faculty of Medicine in Hradec Králové
- Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents2016 | First Faculty of Medicine
- Significance of Lymphoma Clinical Registry information potential and limits2004 | Second Faculty of Medicine
- Verification of Survival Predictors in Elderly Patients with Myelodysplastic Syndrome from Outpatient Clinical Practice2018 | First Faculty of Medicine
- Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group2017 | Third Faculty of Medicine
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes2021 | First Faculty of Medicine
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study2019 | First Faculty of Medicine
- PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group2017 | Third Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
- PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial2021 | Third Faculty of Medicine